Alizyme Therapeutics Limited

Alizyme is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focussed on obesity and related diseases, such as diabetes, and on gastrointestinal disorders including irritable bowel syndrome, inflammatory bowel disease and mucositis, a serious side effect of cancer therapy.

Alizyme takes drug product candidates from an early stage into clinical development with the objective of demonstrating their efficacy in patients and providing a comprehensive data package to support the further development and commercialisation of the drug. Alizyme owns the intellectual property rights to all four drug products currently in clinical trials and has an exclusive worldwide licence to the COLAL™ drug delivery system.



At a suitable stage Alizyme aims to license its products to pharmaceutical companies that have the ability to complete the clinical development of the product, to gain approval from the regulatory authorities and to successfully market the product.



Alizyme has developed its business with a high emphasis on outsourcing, controlled by its core management team and specialist advisors. Rather than establish its own laboratories and development facilities, it has worked with collaborators and service providers such as contract research organisations. This has the benefit of allowing Alizyme to focus its investment onto its development programmes in a cost effective way.

Contact Details: Granta Park, Great Abingdon Cambridge Cambridgeshire CB1 6GX United Kingdom Tel: 44 1223 896000 Fax: 44 1223 896001 Email: info@alizyme.co.uk WWW: www.alizyme.co.uk/

Recent Publications by Alizyme Therapeutics Limited:
Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. BACKGROUND AND OBJECTIVE: Renzapride (ATL-1251), a novel benzamide, is...	7th May, 2008	Alizyme Therapeutics	Drugs R D. 2008;9(1):37-63.
The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. The cardiac safety of renzapride, a novel benzamide currently under...	27th February, 2008	Alizyme Therapeutics	J Int Med Res. 2007 Nov-Dec;35(6):848-66.

BioNews Results for Alizyme Therapeutics Limited:
TechMARK movers: Brain disease scare sinks Elan	ShareCast:  Aug 1 2008 1:41PM Matching: alizyme therapeutics
Ark gains on hopes for cancer drug	The Independent:  Jul 30 2008 11:15PM Matching: alizyme therapeutics

Alizyme Therapeutics Limited Patents:
US Patent No.	Title
7407954	Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
7189852	Synthesis
6916808	2-thio-4h-3, 1-benzoxazin-4-one derivatives for use as enzyme inhibitors
6656934	2-amino-benzoxazinone derivatives for the treatment of obesity
6624161	2-Oxy-benzoxazinone derivatives for the treatment of obesity
→View more Alizyme Therapeutics Limited patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 355 times since April 2007, the link to the organisation's website has been followed 60 times

Recent Search Terms used to find this page: Alizyme | Alizyme Therapeutics Ltd | alizyme therapeutics | alizyme | www.alizyme . com | alizyme therapeutics careers | Alizyme Therapeutics Limited | Alizyme Therapeutics Limited | alizyme therapeutics | alizyme therapeutics | .

Search for more companies in Cambridge

Search for more companies in Cambridgeshire

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Alizyme Therapeutics Limited